Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Irinotecan + Temozolomide in Relapsed/Refractory Ewing's Sarcoma
NCT05440786Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of abemaciclib in Ewing sarcoma, sponsored by Eli Lilly and Company. Started Sep 2022; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT05440786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440786.